Advances in biological techniques have potentiated great progresses in understanding the interaction between human beings and the ∼ 10 to 100 trillion microbes living in their gastrointestinal tract: gut microbiota (GM). In this review, we describe recent emerging data on the role of GM in hematopoietic stem cell transplantation, with a focus on immunomodulatory properties in the immune system recovery and the impact in the development of the main complications, as GvHD and infections.
INTRODUCTION
The microorganisms living in association with the human body are collectively called microbiota. Human beings share a close symbiotic relationship with ∼ 10 to 100 trillion microbes living in their gastrointestinal tract. Advances in biological techniques with the introduction of massively parallel next-generation sequencing (NGS) provided new insights into the composition and complexity of the gut microbiota (GM) by identifying bacterial taxons that are not readily cultivated in vitro.
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The microbiota plays an important role in human health and disease. Particularly, GM is involved in energy harvest and storage, and in metabolic functions, 4 limits the access of enteropathogens to the gastrointestinal tract 5 and influences host immunity, being strategic to the education and preservation of our immune homeostasis. 6, 7 Considering the close cross talk between GM and the immune system, an emerging role has been increasingly attributed to GM after hematopoietic stem cell transplantation (HSCT). New insights have been achieved over the past years on the role of GM on immune recovery after HSCT and onset of infections and GvHD.
In this review, we provide an update on the biology of immune homeostasis in relation to the microbiota and HSCT. Methodologies of characterization of GM are summarized with a comprehensive review of the available literature evaluating the impact of GM on HSCT outcome.
METHODOLOGICAL APPROACH TO GUT MICROBIOTA CHARACTERIZATION
In the past years, new culture-dependent approaches for GM characterization have been developed, allowing an increase in the cultivable fraction of the ecosystem up to the 50%. 8 However, it is a matter of fact that, nowadays, the method elected to conduct a GM study still remains the deep sequencing of the microbial DNA extracted from stool samples, 9 the only approach allowing disclosure of the whole-biological complexity of the ecosystem.
Deep sequencing of microbial DNA is principally carried out by the NGS-based technologies, essentially 454-pyrosequencing (Life Sciences-Roche, Branford, CT, USA), Illumina (San Diego, CA, USA) and Ion Torrent NGS platforms (Thermo Fisher Scientific, Waltham, MA, USA). Both these technologies merge the low cost per sequence with the high-throughput sequencing of short DNA fragments.
The molecular assessment of the human GM, principally relies on two approaches of NGS of microbial DNA, the sequencing of the V3-V4 regions of 16S ribosomal DNA gene, which allows reconstructing the phylogenetic structure of the ecosystem.
The description of the GM compositional structure by 16S ribosomal DNA sequencing involves a robust and wellconsolidated pipeline, 10 including DNA extraction from stool, PCR amplification of the V3-V4 region of the 16S ribosomal DNA, library preparation, DNA sequencing, bioinformatics and biostatistics analyses. 11 Besides providing the compositional structure of the GM ecosystem at different phylogenetic levels (from phylum up to the genus level), the Quantitative Insights Into Microbial Ecology (QIIME) pipeline allows to compute the interindividual diversity (alpha-diversity) and the intra-individual diversity (beta-diversity) of the ecosystem. Both parameters are key factors to describe the configuration of the gut microbial ecosystem. The first is the most relevant factor to define a dysbiotic GM structure, which is always characterized by a reduction of the ecosystem diversity. 12 The second is a fundamental factor to describe and quantify the overall compositional differences between groups of subjects, such as in case control studies exploring GM-associated compositional deviations.
By shotgun NGS of the microbial DNA extracted from stools, it is possible to characterize the GM metagenome, defined as the overall genome content of GM microbes. [13] [14] [15] [16] Even if a giant sequencing effort is necessary, the characterization of the GM microbiome allows provision of useful information on the functional configuration of the ecosystem, which can be easily translated into the overall metabolic propensity. 17 
THE RELATIONSHIP BETWEEN GUT MICROBIOTA AND THE HOST DEFENSE
The gastrointestinal barrier is the largest surface of the human body, and, in addition to the absorptive role, it provides several different functions such as regulation of microbial colonization and mucosal immune responses. GM is controlled by specialized intestinal epithelial cells (IECs), secretory goblet cells and Paneth 1 cells, through the production of an apical mucous layer, the secretion of broadly targeted antimicrobial proteins (AMPs) and the transcytosis of secretory IgA. [18] [19] [20] [21] The composition and products of GM can be considered an extension of the self and have unexpected effects on the immune system. For example, two supposedly genetically identical organisms, such as same-sex inbred mice, can have widely different metabolic and inflammatory responses, depending on the structure of their microbiota. 22 In a condition of immune homeostasis, mutualistic GM components communicate with the gut epithelium and underlying lymphoid tissues, favoring a normal function of immune phenotype with no expression of disease. 23 On the contrary, GM dysbiosis can trigger, or predispose to, several inflammatory disorders, as inflammatory bowel diseases, asthma, autoimmune arthritis and diabetes. [24] [25] [26] [27] In the gut lumen, a complex link between the immune system and the microbiota is spread over several levels. The immune system response can be mediated by the recognition of microbial ligands or by a direct interaction between cells of the immune system and luminal, and components of the microorganisms, or throughout the interaction with their metabolic end products, such as the short-chain fatty acids (SCFA). The final balance among all of these signals may favor the immune tolerance or an inflammatory immune response. 28 One example of this interaction is represented by IECs, which integrate commensal bacteria-derived signals into antimicrobial and immunoregulatory responses by recognition of microbial ligands by Ag-independent pattern recognition receptors (PRRs). PRRs are receptors, which specifically recognize and bind distinctive microbial molecular ligands, such as lipopolysaccharide, flagellin, peptidoglycans and formylated peptides. The most studied PRRs are toll-like receptors (TLRs). In addition to IECs, TLRs are also expressed cells of the innate immune system (macrophages and dendritic cells (DCs)) and cells of the adaptive immune system (T-and B cells). Functional consequence of TLR engagement depends on the responding cell type of the cell where the ligand is encountered. Unlike pathogens that use TLR pathways to trigger inflammation, commensal bacteria exploit the TLR pathway to maintain intestinal homeostasis. 29, 30 Another example is represented by microfold cells, specialized IECs concentrated in the follicle-associated epithelium, 31 which continuously sample luminal Ags for presentation to the underlying dendritic cells. [32] [33] [34] The activation of these cells, by commensal bacteria, such as Lactobacillus reuteri and L. casei, modulate immune system by the differentiation of naive T-helper (Th) cells into Treg cells. 35 Immune response is also coupled with information coming from the local gut throughout the capability of DCs of monitoring availability of ATP derived from commensal bacteria. 36 DC-associated sensors of cellular energy resources are regulated by AMP-activated protein kinases, as mammalian target of rapamycin. This pathway affects both the innate and adaptive arms of the immune system. Indeed, in response to ATP stimulation, the secretion of interleukin (IL)-6 and IL-23 by activated DCs induces Th17 cell differentiation, 37 and inhibits Treg development and memory T-cell formation, promotes the differentiation of Th1, Th2 and Th17 cells, and regulates CD8+ T-cell trafficking. 36, 38 All these mechanisms are only a part of the complex interaction regulating local and systemic inflammatory response, arising from the relationship between immune system and GM, and underscore how the GM exerts a key role in the defense system of the host.
THE IMMUNOMODULATORY EFFECT OF GUT MICROBIOTA ON THE ANTICANCER IMMUNE RESPONSE
The role of microbiota in shaping the systemic immune response was studied in a cancer model and astonishing data suggested that GM composition may significantly influence the anticancer immune response. Commensal bacteria differentially affect the type of inflammatory tone required for the response to traditional chemotherapeutic agents, as cyclophosphamide, 39, 40 and to antibodies blocking immune inhibitory pathways, as cytotoxic T-lymphocyte antigen (CTLA)-4 and the axis between programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1). 41, 42 In particular, cyclophosphamide modifies GM composition in the small intestine and induces the translocation of selected Gram-positive bacteria into secondary lymphoid organs. These bacteria stimulate the generation of a specific immune responses mediated by 'pathogenic' Th17 cells and memory Th1. Mice that were germ-free or treated with antibiotics to kill Gram-positive bacteria had a reduced Th17 responses, and their tumors were resistant to cyclophosphamide. Adoptive transfer of Th17 cells partially restored the antitumor efficacy of cyclophosphamide. 39 In another experiment with antibiotic-treated or germ-free mice, tumor-infiltrating myeloid-derived cells responded poorly to platinum chemotherapy. This results in lower cytokine production and tumor necrosis, and deficient production of reactive oxygen species and cytotoxicity after chemotherapy. Thus, optimal responses to cancer therapy require an intact commensal microbiota, mediating its effects by modulating myeloid-derived cell functions in the tumor microenvironment. 40 Also the growth of melanoma was different in mice-harboring distinct commensal GM compositions. In this experiment, the presence of commensal Bifidobacterium modulates T-cell infiltration of the tumor, resulting in favorable outcomes and enhanced response to immunotherapy with PD-L1 antibodies. 41 The immunostimulatory role of GM composition was also studied in a mouse model of melanoma treated with monoclonal Ab directed against CTLA-4, a different negative regulator of T-cell activation. The GM composition, particularly the presence of Bacteroidales, affects Th1 immune responses, facilitating tumor control in mice and patients, although sparing intestinal integrity. Tumors in antibiotic-treated or germ-free mice did not respond to CTLA blockade. This defect was overcome by gavage with B. fragilis by immunization with B. fragilis polysaccharides, or by adoptive transfer of B. fragilis-specific T cells. 42 All these observations support the idea that the composition of gut microbes could be manipulated for stimulate commensals associated with antitumor immunity.
GUT MICROBIOTA AND HEMATOPOIETIC STEM CELL TRANSPLANTATION Evolution of GM composition during HSCT GM structure before the transplantation well approximates the commonly reported healthy-like profile, in terms of richness and diversity of the ecosystem 1 both in adults and children. [43] [44] [45] It is also efficient in terms of SCFA production, the most reliable biomarker of microbiota-host mutualistic configuration. 6 This observation demonstrates the high dynamicity of the GM, which recovers its layout before the HSCT, in spite of the treatments received by these patients in terms of chemotherapy and antibiotic exposure ( Figure 1 ).
HSCT and all the related standard procedures, such as conditioning regimen, antibiotic exposure, diet and anti-acid prophylaxis, represent an upset event with a profound modification of the GM structure and disruption of its mutualistic asset. 43, 44 In particular, during the neutropenic period, the species richness of the gut ecosystem (alpha-diversity) decreased of~30% compared with the pre-HSCT. The GM structure is characterized by a massive 'invasion' of new species and o10% of the pre-existing species being conserved. These alterations bring about a loss of the individual layout. 43 Extreme shifts in the intestinal microbiota were observed in two-third of patients, documenting either Enterococcal or streptococcal domination. 46 This deep modification of GM is also accompanied by a loss in the abundance of health-promoting species, for example Faecalibacterium and Ruminococcus. 43 Specific factors were identified to be associated with a specific GM layout following HSCT. Increase in Enterococci and simultaneous loss of commensal bacteria was found in patients receiving both oral ciprofloxacin and systemic broad-spectrum antibiotics. A possible explanation of this phenomenon is that the commensal bacteria are important inducers of AMPs, such as α-defensins produced by Paneth cells, selectively active against noncommensal Gram-negative and Gram-positive bacteria, 47 targeting highly conserved and essential features of bacterial biology.
After prolonged use of these antibiotics, the presence of commensal bacteria in GM declines and, consequently, also AMPs, such as C-type lectin regenerating islet-derived protein III α (REG3α), which is the major peptide preventing Enterococcal overgrowth. 48 Also in patients with gastrointestinal GvHD a marked reduction in the secretion α-defensins due to the allogeneic T-cell response has been described, resulting in profound damage to Paneth cells. As mentioned above, these peptides regulate the pathogen flora in the gut, although preserving commensals. So the final result is the loss of diversity of endogenous mutualists, paving the way to the proliferation of alloctonous opportunistic bacteria. 49 Interestingly, a small percentage of the bacterial species resists during HSCT and is conserved throughout the whole longitudinal survey, as a consequence of the ecosystem being upset, and 'reappear' later on. These persisting species could act as 'founders' to reconstruct a healthy-like ecosystem once conditions allow. 43 Indeed, Bacteroides species, which are the most represented among the persisting ones, are known to act as a bacterial reservoir to maintain long-term colonization or repopulate the gut after the ecosystem disruption. [50] [51] [52] On the contrary, the great majority of the newly acquired phylotypes, invading temporarily the ecosystem, is replaced later on during the GM recovery. In fact, after a period of~60 to 100 days after HSCT, the ecosystem recovers the initial amount of richness, underlying once again the high dynamicity of the GM.
The role of GM in the HSCT The relevant impact of GM in the HSCT was recently demonstrated. Particularly, the diversity of the gut microbial community proved to be a reliable predictor of the overall mortality in transplanted patients. Indeed, in a cohort of 80 transplanted adults, low-, intermediate-and high-diversity intestinal diversity of the GM at the engraftment defined three groups with different overall survival at 3 years, 36, 60, and 67%, respectively. 45 The increase of the mortality rate in this study was primarily due to transplant-related causes, suggesting a link between that lack of microbial diversity and infection and/or GvHD. 45 Also the level of urinary excretion of 3-indoxyl sulfate, an indirect marker of GM health, was found to predict poor, early and long-term outcomes of transplanted patients. 53 3-Indoxyl sulfate is a product of L-tryptophan metabolism by commensal bacteria expressing tryptophanase and acts as intercellular signal in microbial communities, modulating mucosal barrier function and expression of pro-and anti-inflammatory genes in the IECs. Low 3-indoxyl sulfate levels were the result of a disrupted GM signature, and were associated with significantly higher transplant-related mortality and worse overall survival 1 year after HSCT. 53 (Clinical studies evaluating GM in HSCT are summarized in Table 1 ).
GvHD
GvHD is associated with major shifts in the composition of the GM both in murine and human recipients of HSCT. 54 In mouse models, specific dysbiosis associated with GvHD are characterized by loss of the overall diversity, increase of members of the bacterial orders Enterobacteriales (Escherichia, Klebsiella, and Enterobacter species) and Lactobacillales (Lactobacillus, Enterococcus and Streptococcus species), and reduction of obligate anaerobic bacteria from the order of the Clostridiales (Faecalibacterium, Roseburia, Ruminococcus and Blautia). 49, 54, 55 An experimental mouse model demonstrated that microbiota, in turn, could modulate the severity of intestinal inflammation. Indeed, GvHD was aggravated eliminating Lactobacillales from the flora of the mice before HSCT, whereas the reintroduction of predominant species of Lactobacillus mediated significant protection against GvHD. 54 Another elegant experimental mouse model compared either L.rhamnosus GG or ciprofloxacin alone from day 7 before transplantation and throughout the post-transplantation period, or ciprofloxacin for 7 days, followed by L. rhamnosus GG for the post-transplantation period showing that oral administration of L. rhamnosus GG before and after transplantation results in improved survival and reduced acute GvHD. Furthermore, culturing of mesenteric lymph node tissue, as a sign of an affected mucosal barrier function due to the Figure 1 . Hematopoietic stem cell transplantation (HSCT) temporarily disrupts diversity, individual signature and short-chain fatty acid production of the gut microbiota. HSCT resulted in a profound disturbance of the gut ecosystem that can be measured in the loss of~30% in average of the pre-HSCT alpha-diversity. A full color version of this figure is available at the Bone Marrow Transplantation journal online.
Gut microbiota and hematopoietic stem cell transplantation D Zama et al To analyze the risk of bacteremia during HSCT.
• Bloodstream infection was detected in 22 (23.4%) patients: 9 were due to VRE, 10 to Gram-negative bacteria.
• Enterococcal domination (40.4% of pts) increased the risk of VRE bacteremia. Risk factors were leukemia diagnosis and metronidazole administration.
• Proteobacterial domination (12.8% pts) increased the risk of Gam-negative bacteremia. Proteobacteria domination was reduced 10-fold by fluoroquinolone administration. Taur et al. 53 
adults
Fecal samples collected within 7 days following stem cell engraftment.
PCR followed by sequencing for microbiota analysis.
To analyze the impact of GM diversity on mortality following HSCT.
• The diversity of the intestinal microbiota at engraftment is an independent predictor of the mortality.
• On the basis of the overall bacterial diversity, pts were classified in high-, intermediate-, low-diversity groups, which, respectively, correspond to survival at 3 years 36, 60 and 67%.
Holler et al. 52 
adults
Fecal samples collected at a min. of three time points: before HSCT, during aplastic period, and on days 21-28.
NGS of the V3 region of the 16s rRNA gene, PCR of Enterococci and analysis of urinary indoxyl sulphate.
To monitor microbiome shifts in the course of allogeneic HSCT.
• A major loss of bacterial diversity contributed to the intestinal inflammation.
• Increase in the proportion of Enterococci and decrease in the commensal bacteria was prominent in patients who developed GI GvHD or suffered from active GI GvHD. To evaluate the relationship between GvHD and the fecal bacterial composition after HSCT.
• Increased bacterial diversity was associated with reduced GVHD-related mortality.
• Blautia abundance was associated with reduced GvHD lethality and improved the overall survival. Loss of Blautia was associated with treatment with antibiotics that inhibit anaerobic bacteria and receiving total parenteral nutrition for longer durations.
Weber et al. 61 
Urinary 3-IS was performed by reversed-phase liquid chromatography-electrospray ionization-tandem MS at the time of HSCT and early thereafter.
To evaluate the correlation of urinary 3-IS levels as predictors of outcome of HSCT.
• Low urinary 3-IS levels between days 0 and 10 after HSCT were associated with poor, early and long-term outcome because of an increased frequency of lethal complications mostly as a consequence of GI GvHD. Biagi et al. 51 
children
Fecal samples collected pre-HSCT and at least three times after HSCT.
V4 region of the 16S rRNA gene was amplified and subsequently NGS was performed. GC-MS used to determine SCFA production.
To analyze the connection between the process of GM reconstruction GvHD in pediatric patients.
• GvHD and non-GvHD subjects had a different temporal trajectory of GM ecosystem recovery after HSCT.
• Specific dysbiosis associated with GvHD: drop of Faecalibacterium and increase of Enterococcus.
• In pre-HSCT samples, non-GvHD pts had higher abundances of mutualists propionate-producing Bacteroidetes, which persist during the HSCT-induced ecosystem disruption.
Haris et al. 82 
adults
Fecal samples from conditioning regimen to day +35 days after HSCT.
V1-V3 region of the 16 S rRNA gene was amplified by means of PCR. Purified PCR products were sequenced on a 454 GS FLX Titanium platform.
To investigate whether changes in GM are associated with PCs after HSCT.
• 112 PCs occurred in 66 subjects.
• High co-morbidity index, fluoroquinolones, low-GM baseline diversity and Gammaproteobacteria domination of fecal microbiota, which included common respiratory pathogens, predicted PCs.
• In separate analyses, low-baseline diversity was associated with PCs occurring pre-engraftment, although Gammaproteobacteria domination predicted PCs post engraftment and the overall mortality.
Abbreviations: 3-IS = 3-indoxyl sulphate; GC-MS = gas chromatography-mass spectrometry; GI = gastrointestinal; GM = gut Microbiota; HSCT = hematopoietic stem cell transplantation; min. = minimum; NGS = next-generation sequencing; pts = patients; PCs = pulmonary complications; rRNA = ribosomal RNA; SCFA = short-chain fatty acids; VRE = vancomycin-resistant Enterococcus.
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intestinal inflammation, revealed a reduced translocation of enteric bacteria. 56 This observation indicates that antibiotic exposure before HSCT modifies the risk of intestinal GvHD and that targeted flora reintroduction may potentially reduce the severity of GvHD.
Data found in humans, both adults and children are in line with those found in mouse models. In particular, GvHD onset was associated with a drop in the abundance of the known health-promoting Faecalibacterium of the order of Clostridiales and high percentages of Enterococcus. 43, 44 These latter microorganisms are potential contributors to increased intestinal inflammation in both mice and humans, by induction of IL-1 and IL-6 production, resulting in subsequent Th1 and Th17 activation. 44 Thus, the predominance of Enterococci together with the reduction of commensals Faecalibacterium and Clostridiales, considered to be important for maintaining tolerance against the intestinal microbiome, 57, 58 can favor the consolidation of intestinal inflammation. On the other hand, intestinal flora diversity and a high percentage of the bacterial genus of the Blautia of the order of Clostridiales in the GM in the early period after HSCT were associated with reduced GvHD lethality. 59 Finally, we have successfully demonstrated different temporal trajectory of GM ecosystem recovery after HSCT between GvHD and non-GvHD subjects. 43 Interestingly, GvHD and non-GvHD subjects differ also in the pre-HSCT GM signature, which is projected in the distinctive trajectory of post-HSCT GM reconstruction. Non-GvHD subjects have a higher abundance of members of the Bacteroidetes phylum, known to produce SCFA from dietary fiber, 55 influencing both the magnitude and the quality of the immune response. 60 SCFA are end products of microbial fermentation of complex plant polysaccharides that cannot be digested by humans alone, because our genomes do not encode an adequate repertoire of glycoside hydrolases. 61 SCFA are one of the clearest examples of how diet and nutrient processing by the microbiota combine to shape immune responses.
The complex polysaccharides fermenters members of the Clostridia species are associated with the increased production of SCFA (acetate, propionate and butyrate), and consequent expansion and activation of colonic regulatory T cells (Tregs) by IECs production of transforming growth factor-β. 57, 62 In particular, butyrate modify the cytokine production profile inducing potent anti-inflammatory cytokine IL-10, induce colonic Tregs through upregulation of gut-homing molecules 61 and Foxp3. 63 It also promotes intestinal epithelial barrier integrity, 64 limiting exposure of the mucosal immune system to luminal microbes, preventing aberrant the inflammatory responses and enhancement of hematopoiesis of DC precursors with a low ability to activate the allergy-related Th type 2 cells. 26 Interestingly, dysbiosis of patients with GvHD, share similar features to those found in patients with inflammatory bowel diseases. Indeed, reduced microbial richness, impaired abundance of butyrate producers and relative abundance of Gram-positive bacteria (especially Clostridium clusters IV and XIVa) were associated with intensity of intestinal inflammation in both. 65 The levels of Enterobacteriaceae at the diagnosis were negatively correlated with follow-up clinical outcomes and increased abundance was associated with the grade of inflammation. 66 Like in GvHD also in Crhon's disease, lower levels of Firmicutes, such as Faecalibacterium prausnitizi a major producer of the SCFA butyrate, were found. 67, 68 Infection Pretransplant conditioning transiently ablates circulating granulocytes and monocytes, and markedly increases susceptibility to disseminated infections. 69, 70 In addition, radiation and chemotherapy-mediated destruction of gut epithelial cells enables commensal microbes to invade underlying tissues and the bloodstream. 71 As a result, systemic bacterial infections are frequent during the early transplant period. 72 Vancomycin-resistant Enterococcus (VRE), viridians group Streptococcus and aerobic Gram-negative bacteria are the most common causes of bloodstream infection following HSCT. 73, 74 The complex commensal microbial populations colonizing the human intestine provide resistance to infection, whereas the increase of pathogens in the gut favors the development of resistant bacteria. 75 Recently, Taur et al.
46
characterized longitudinally the fecal microbiota of 94 patients undergoing HSCT and observed extreme shifts in the intestinal microbiota in two-thirds of patients with either Enterococcal or Streptococcal domination, with a cutoff definition of 30% for intestinal domination. These perturbations correlated with subsequent development of a corresponding bloodstream infection with either VRE or Gram-negative bacteria. Interestingly, viridians group Streptococci and VRE were historically the most frequently encountered bloodstream infections in HSCT patients during the pre-engraftment period. 72, 73, 76 Enterococcal domination was associated with an increased risk of VRE bacteremia, whereas intestinal domination by Proteobacteria increased the risk of bacteremia with aerobic Gram-negative bacilli. In almost 50% of the patients with bacteremia, a preceding intestinal domination by a corresponding organism has been demonstrated and the median time between domination and bacteremia in these patients was 7 days. 46 The role of antibiotics administered during HSCT on GM diversity was extensively evaluated. Metronidazole was associated with increased risk of Enterococcal domination, 77 supporting the idea that anaerobic bacteria contribute to colonization resistance. 78 Fluoroquinolones protected against proteobacterial domination, reducing the risk of Gram-negative bloodstream infections. This finding supports prior studies of fluoroquinolone prophylaxis in neutropenic patients 79 and sheds light on the mechanism of protection.
Pulmonary complications
Several studies have shown gut dysbiosis can trigger inflammation in asthma and allergic airways diseases, 26 cystic fibrosis 80 and infection-mediated lung inflammation 81 also in the absence of lung colonization or infection. Intestinal permeability may be implicated in the translocation of bacteria and/or microparticles, such as lipopolysaccharide, on the pathway to acute lung injury and sepsis-associated acute respiratory distress syndrome.
Harris et al. 82 recently investigated the role of GM in gut-lung cross talk after HSCT aiming to evaluate the role of GM in the onset of pulmonary complications (PCs). They found 112 PCs (defined by radiographic parenchymal abnormalities in the setting of respiratory signs/symptoms and associated mortality) in 66 allotransplanted patients. High co-morbidity index, fluoroquinolones, low-baseline diversity and interestingly Gammaproteobacteria domination of fecal microbiota predicted PCs. Gammaproteobacteria is a class of bacteria that includes respiratory pathogens such as Klebsiella pneumoniae and K. oxytoca. These findings may suggest direct translocation of bacteria to the lungs during early transplant or indirect lung injury caused by microbiota stimulation of a systemic or local inflammatory response as possible mechanisms; alternatively, associations might reflect overall microbiota status or antimicrobial use.
Graft-versus-tumor Considering that intestinal bacteria are modulators of systemic immune responses Peled et al. 83 also hypothesized that components of the intestinal flora could be associated with graft-versus-tumor activity, modifying relapse rate after HSCT. For the first time, an association between relapse after HSCT and GM composition was found. In a cohort of 160 allografted adults affected by oncological disease, the taxons most significantly associated with freedom from relapse were members of the human oral flora, including Streptococcus anginosus. Patients with higher abundance of this bacterium had less relapse after transplantation, whereas Enterococcus faecium was associated with the increased risk of relapse. 83 
FUTURE PERSPECTIVES
The increasing knowledge of the relationship between GM and immune system opens countless diagnostic and therapeutic opportunities in transplanted patients. Several diagnostic and therapeutic strategies can be hypothesized to transfer from the bench to the bedside of this knowledge.
Identification of high-risk patients with an increased probability of transplant-related mortality could help to prevent or treat early life-threatening complications linked to dysbiosis of the GM. A fast biomarker able to determine the eubiotic condition of the GM would be an invaluable tool. Recently, urinary 3-indoxyl sulfate levels, a marker of microbiota health, were demonstrated to be able to identify high-risk patients in the early period after HSCT, 53 although concentration of REG3α, an antimicrobial product produced by IECs, was correlated with lower gastrointestinal GvHD and allowed prediction of the response to therapy for GvHD. 84 Potential interventions could be hypothesized both before and after HSCT and range from the use of prebiotic, such as fiber-rich diet, and probiotics, fecal microbiota transfer (FMT), to the targeted antibiotic therapies tailored on the composition of the GM.
Probiotics have been also demonstrated to modify the composition of the GM and thereby mediate anti-inflammatory effects. Although there are some safety concerns about the use of probiotics in immunodeficient patients, strategies to reintroduce complex microbial populations into the gut following HSCT could be of benefit. Their use may potentially offer a novel approach to attenuating GvHD and the risk for bloodstream infections. The administration of probiotic L. plantarum has been tested in a large cohort of children undergoing allogeneic HSCT, which received daily supplementation as 1 week before transplant until day +14. Safety and feasibility were demonstrated and, most of all, no cases of L. Plantarum bacteremia were observed. 85 FMT consists of the introduction of a fecal suspension derived from a healthy donor. It was successfully in a patient with recurrent Clostridium difficile-associated disease. 86 After FMT, the bacterial composition of the recipient resulted highly similar to that of the donor, suggesting that the bacteria of the donor can inhabit their requisite niches with renewal of the microbial communities present. Although concerns about infectious organisms transmitted through FMT will need to be addressed, two HSCT patients successfully received FMT. 87, 88 In addition, strategies to manipulate the GM signature could be developed aiming to favor a mutualistic layout. For instance, a recent study demonstrated that the GM can rapidly respond to short-term consumption of diets composed entirely of animal or plant products or to modification of fermentable oligosaccharide, disaccharide, monosaccharide and polyol intake. 89, 90 In these studies, alteration of the diet overwhelmed the inter-individual differences in microbial gene expression. Thus, a fiber-rich diet or a modification of dietary fermentable saccharide intake, pre-HSCT and possibly early after HSCT, could be utilized to favor SCFA-producing bacteria groups that might be involved in the modulation of the immunological recovery after HSCT as highlighted in patients with Crohn's disease. 89, 90 Much work remains still to do to better understand the role of intestinal bacteria in immune reconstitution and in the risk of infection after HSCT, but the increasing knowledge of the role of GM should pave the way to targeting the microbiota in a rational way in experimental and clinical studies, necessary to explore its beneficial effects in HSCT.
